Probiotics plus budesonide for IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether adding probiotics to a standard treatment (budesonide, an enteric-coated steroid) can help reduce protein in the urine of people with IgA nephropathy. It aims to see if the combination is more effective than budesonide alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- A kidney biopsy has confirmed you have IgA nephropathy.
- Your urine protein is at least 0.75 grams per day (or a protein/creatinine ratio of 0.5 or higher).
- Your kidney function (eGFR) is 30 mL/min or higher.
- You have not used antibiotics, steroids, or other immune-suppressing drugs in the last 3 months.
- You agree to use effective birth control if you are fertile.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether immunosuppressive therapy (medicine that calms the immune system) helps people with IgA nephropathy and moderately to severely reduced kidney function. It is intended for adults with confirmed IgA kidney disease who still have significant protein in the urine despite standard blood-pressure kidney protection treatment.
This trial tests whether a special steroid capsule called budesonide can help treat IgA nephropathy, a kidney disease where your immune system damages the kidneys. You would take this medication along with standard care to see if it slows kidney damage and reduces protein in your urine.
This trial tests starting a special form of budesonide (Nefecon) early in people with IgA nephropathy, a kidney disease. The goal is to see if it can reduce protein in the urine and protect kidney function.
This trial tests whether mycophenolate mofetil, an immunosuppressant drug, can reduce protein in the urine of people with IgA nephropathy that hasn't responded to other treatments. It aims to help slow down kidney damage.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
Hear when a new Glomerulonephritis, IGA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.